Cover Image

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed...

Full description

Saved in:
Bibliographic Details
Main Authors: Fuchs, Michael (Author) , Jacob, Anne Sophie (Author) , Kaul, Helen (Author) , Kobe, Carsten Andreas (Author) , Kuhnert, Georg Eckhard (Author) , Pabst, Thomas (Author) , Greil, Richard (Author) , Bröckelmann, Paul Jan (Author) , Topp, Max S. (Author) , Just, Marianne (Author) , Hertenstein, Bernd (Author) , Soekler, Martin (Author) , Vogelhuber, Martin (Author) , Zijlstra, Josée M. (Author) , Keller, Ulrich (Author) , Krause, Stefan W. (Author) , Dührsen, Ulrich (Author) , Meißner, Julia (Author) , Viardot, Andreas (Author) , Eich, Hans Theodor (Author) , Baues, Christian Manfred (Author) , Diehl, Volker (Author) , Rosenwald, Andreas (Author) , Buehnen, Ina (Author) , Tresckow, Bastian von (Author) , Dietlein, Markus (Author) , Borchmann, Peter (Author) , Engert, Andreas (Author) , Eichenauer, Dennis Alexander (Author)
Format: Article (Journal)
Language:English
Published: 16 October 2023
In: Leukemia
Year: 2023, Pages: 1-8
ISSN:1476-5551
DOI:10.1038/s41375-023-02064-y
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41375-023-02064-y
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41375-023-02064-y
Get full text
Author Notes:Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Georg Kuhnert, Thomas Pabst, Richard Greil, Paul J. Bröckelmann, Max S. Topp, Marianne Just, Bernd Hertenstein, Martin Soekler, Martin Vogelhuber, Josée M. Zijlstra, Ulrich Bernd Keller, Stefan W. Krause, Ulrich Dührsen, Julia Meissner, Andreas Viardot, Hans-Theodor Eich, Christian Baues, Volker Diehl, Andreas Rosenwald, Ina Buehnen, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert and Dennis A. Eichenauer
Description
Summary:The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n = 328) and 86.7% after ABVD alone (n = 300; HR = 2.05 [1.20-3.51]; p = 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p = 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n = 353; 94.0%) than in PET-2-positive patients (n = 340; 90.3%; p = 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n = 571; 94.0% vs. DS ≥ 4: n = 122; 83.6%; p < 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.
Item Description:Im Web of Science ist der DOI fälschlich als 10.1038/s41375-023-02064 angegeben
Gesehen am 13.12.2023
Physical Description:Online Resource
ISSN:1476-5551
DOI:10.1038/s41375-023-02064-y

Similar Items